Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences (NASDAQ: IART) reported Q1 2021 revenues of $360.1 million, a 1.6% increase year-over-year. GAAP earnings per diluted share rose to $0.53 from $0.11 in Q1 2020. The company raised its 2021 revenue guidance by $5 million, targeting between $1,525 million and $1,535 million. Adjusted gross margin was 67.3%, down from 68.3% last year, influenced by revenue shifts and COVID-19 impacts. Adjusted EBITDA increased to $89.9 million, enhancing margins to 25.0%.
Integra LifeSciences (Nasdaq:IART) supports the FDA's recent safety communication regarding acellular dermal matrix (ADM) products in breast reconstruction. The company's SurgiMend Collagen Matrix is FDA-cleared for specific surgical applications but is not approved for breast reconstruction. Integra emphasizes the importance of patient-doctor discussions about medical technologies. The firm is dedicated to delivering safe and effective products and aims for future clearance for breast reconstruction applications, collaborating with healthcare professionals to enhance women's health.
Integra LifeSciences (NASDAQ: IART) announced its first quarter 2021 financial results will be released on April 28, 2021, prior to market open. The management will host a conference call at 8:30 a.m. ET for investors and analysts. Access will be through a dedicated phone line or a webcast on Integra's website. A replay of the call will be available until May 8, 2021. Integra specializes in regenerative tissue technologies and neurosurgical solutions, providing a wide range of medical products aimed at enhancing patient care.
Integra LifeSciences Holdings Corporation (Nasdaq:IART) has appointed Shaundra Clay to its board of directors as of April 1, 2021. Clay, a seasoned executive with extensive experience in finance and strategy, previously held significant roles at Beam Suntory, JP Morgan Chase, Eli Lilly, and Medtronic. Her expertise is expected to enhance the board's ability to drive financial performance. The announcement highlights the company’s commitment to strong corporate governance and strategic growth in the medical technology sector.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in several upcoming investor conferences. On February 24, 2021, CFO Carrie Anderson will present at the Citi 2021 Healthcare Services Conference at 2:25 pm ET. Following this, she will present at the Raymond James 42nd Annual Conference on March 3, 2021, at 7:30 am ET. Lastly, COO Glenn Coleman will speak at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 1:50 pm ET. Webcast details are available on their investor relations website.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q4 2020 revenues of $388.6 million, down 1.6% year-over-year, but up 5% sequentially. GAAP earnings per diluted share increased to $1.09, aided by a one-time tax benefit of $59.2 million. Full-year revenues fell 9.6% to $1,371.9 million due to COVID-19 impacts, despite a net income rise to $133.9 million. Cash flows from operations were robust at $203.8 million, with strong liquidity, holding $470.2 million cash. The company is optimistic about growth in 2021, focusing on enhancing operations and product portfolio.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has completed the acquisition of ACell, Inc., enhancing its complex wound management solutions with proprietary MatriStem UBM™ technologies. CEO Peter Arduini emphasizes this acquisition will help address significant clinical challenges in wound care. The legal advisory for the transaction was handled by Sullivan & Cromwell LLP. Integra continues to focus on providing high-quality regenerative tissue technologies and neurosurgical solutions to improve patient care.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its preliminary fourth quarter and full-year 2020 revenue results. The fourth quarter revenue is estimated between $387 million to $389 million, marking a decrease of up to 2.1% year-over-year. Full-year revenue is projected at $1,370 million to $1,372 million, reflecting a 9.7% decline. Despite these figures, the company indicated sequential improvement from Q3 and anticipates growth in 2021 following its recent divestiture of Extremity Orthopedics and acquisition of ACell. Financial results will be fully released on February 18, 2021.
Integra LifeSciences (NASDAQ:IART) has finalized the divestiture of its Extremity Orthopedics business to Smith+Nephew. This strategic move aims to enhance Integra's focus on its core offerings in neurosurgery and regenerative medicine. CEO Peter Arduini emphasized that this divestiture will help create greater value for customers and shareholders. The company is advised by Piper Sandler & Co. as financial advisor and Morgan, Lewis & Bockius LLP as legal advisor. Future performance remains uncertain, with various risks noted, including financial performance projections.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced that CEO Peter Arduini will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 8:20 AM ET. The presentation will be accessible via a live webcast on the company’s investor relations website. Integra specializes in regenerative technologies and neurosurgical solutions, aiming to enhance patient care through its extensive portfolio of products.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
